Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-20 22:30 |
Cellectis modifie sa note convertible de 20 millions de dollars dans le cadre d…
|
French | 60.0 KB | ||
| 2023-01-20 22:30 |
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement wit…
|
English | 90.0 KB | ||
| 2023-01-17 13:10 |
Calyxt et Cibus annoncent la signature d’un Accord de Fusion
|
French | 74.2 KB | ||
| 2023-01-17 13:10 |
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
|
English | 51.5 KB | ||
| 2023-01-09 22:30 |
Monthly information on share capital and company voting rights
|
English | 108.6 KB | ||
| 2023-01-09 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 83.8 KB | ||
| 2023-01-04 23:09 |
Cellectis met en place un programme At the Market sur le Nasdaq
|
French | 95.6 KB | ||
| 2023-01-04 23:08 |
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
|
English | 75.4 KB | ||
| 2022-12-29 22:30 |
Mayflower Bioventures lance sa première spin-off, Primera Therapeutics, en coll…
|
French | 82.0 KB | ||
| 2022-12-29 22:30 |
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Str…
|
English | 84.2 KB | ||
| 2022-12-28 22:30 |
Cellectis obtient un crédit d’un montant de 40 millions d’euros de la Banque Eu…
|
French | 74.9 KB | ||
| 2022-12-28 22:30 |
Cellectis secures a €40 million credit facility from the European Investment Ba…
|
English | 70.6 KB | ||
| 2022-12-22 22:30 |
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Pr…
|
English | 133.4 KB | ||
| 2022-12-22 22:30 |
Cellectis annonce que son produit candidat UCART22, fabriqué en interne, a été …
|
French | 62.1 KB | ||
| 2022-12-16 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 83.5 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
